Key Highlights

  • At the same snapshot the S&P/ASX 200 Health Care index was down 0.37 per cent at 26,536.10, one of six of 11 sectors in the red, and the S&P/ASX 200 slipped 0.26 per cent to 8,953.80.
  • 4DMedical was among the 10 biggest gainers on the index, moving against its own sector.
  • Its two most recent filings were both dated 31 July: a price-sensitive Quarterly Activity Report and Appendix 4C, and a routine update on a proposed issue of securities.
  • ASX data shows a 52-week range of AUD 0.305 to AUD 7.55, and 4DMedical finished FY25 near AUD 0.24 with a Market Value around AUD 112 million.

A rare green tick in a red health sector The contrast is the story. At the same snapshot the S&P/ASX 200 Health Care index was down 0.37 per cent at 26,536.10, one of six of 11 sectors in the red, and the S&P/ASX 200 slipped 0.26 per cent to 8,953.80. 4DMedical was among the 10 biggest gainers on the index, moving against its own sector.

Company Overview

The contrast is the story. At the same snapshot the S&P/ASX 200 Health Care index was down 0.37 per cent at 26,536.10, one of six of 11 sectors in the red, and the S&P/ASX 200 slipped 0.26 per cent to 8,953.80. 4DMedical was among the 10 biggest gainers on the index, moving against its own sector.

Latest Update

No company announcement explains it. 4DMedical lodged nothing with the ASX on 3 August. Its two most recent filings were both dated 31 July: a price-sensitive Quarterly Activity Report and Appendix 4C, and a routine update on a proposed issue of securities. Monday's move therefore reads as continued digestion of that quarterly. One point of basis needs settling. There has been no share consolidation.

Operations and Strategic Direction

Cash receipts from customers were AUD 1.338 million for the June quarter and AUD 5.688 million for FY26. Operating Revenue for the year was AUD 7.2 million, up 23 per cent on the prior corresponding period, at gross margins above 90 per cent. Volumes grew faster than dollars: 105,970 scans in the June quarter, up 43 per cent on the same quarter a year earlier, and 344,075 across FY26, up 77 per cent.

Financial and Market Snapshot

The Balance Sheet has been transformed, though not by trading. Net operating cash outflow was AUD 9.256 million for the quarter, yet cash at 30 June 2026 stood at AUD 277.954 million and it estimated about 30 quarters of funding. A year earlier cash was AUD 6.9 million. That gap was filled with Equity : a AUD 150 million Placement at AUD 3.80 a share in January 2026, an AUD 83 million placement in March alongside CE Mark certification for CT:VQ, and a AUD 30.2 million raise in December 2025.

Broader Context

The next update should clarify whether current developments are translating into measurable progress. Capital allocation remains relevant because delivery must be matched with sufficient financial capacity. Market expectations can change quickly when operational results differ from earlier assumptions. Cash conversion offers another practical measure of the quality of reported Earnings . Customer Demand can change quickly when economic conditions and competitive behaviour shift. Capital allocation remains relevant because every expansion decision carries an Opportunity cost . Management commentary will be weighed against measurable revenue, Margin and cash-flow outcomes. Longer-term progress depends on maintaining service quality while controlling the cost base.

What May Be Watched Next

The FY26 full-year result is due by the end of August; last year's landed on 29 August. Watch the split between recurring software revenue and one-off orders, the cash outflow trend, completion of the contextflow Acquisition and any movement on CPT code status or payer coverage. 9666 is a slow burn, not a near-term earnings driver.

Key Risks

Revenue of AUD 7.2 million against a market value near AUD 2.2 billion prices in years of execution that has not happened yet. Category III CPT codes do not guarantee payment. Reimbursement timing is the largest unknown and sits outside the company's control.